Improved Treatment Options for Glaucoma with Brimonidine-Loaded Lipid DNA Nanoparticles
Standard
Improved Treatment Options for Glaucoma with Brimonidine-Loaded Lipid DNA Nanoparticles. / Schnichels, Sven; Hurst, José; de Vries, Jan Willem; Ullah, Sami; Frößl, Katharina; Gruszka, Agnieszka; Löscher, Marina; Bartz-Schmidt, Karl-Ulrich; Spitzer, Martin S; Herrmann, Andreas.
in: ACS APPL MATER INTER, Jahrgang 13, Nr. 8, 03.03.2021, S. 9445-9456.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Improved Treatment Options for Glaucoma with Brimonidine-Loaded Lipid DNA Nanoparticles
AU - Schnichels, Sven
AU - Hurst, José
AU - de Vries, Jan Willem
AU - Ullah, Sami
AU - Frößl, Katharina
AU - Gruszka, Agnieszka
AU - Löscher, Marina
AU - Bartz-Schmidt, Karl-Ulrich
AU - Spitzer, Martin S
AU - Herrmann, Andreas
PY - 2021/3/3
Y1 - 2021/3/3
N2 - Glaucoma is the second leading cause of irreversible blindness worldwide. Among others, elevated intraocular pressure (IOP) is one of the hallmarks of the disease. Antiglaucoma drugs such as brimonidine can lower the IOP but their adherence to the ocular surface is low, leading to a low drug uptake. This results in a frequent dropping regime causing low compliance by the patients. Lipid DNA nanoparticles (NPs) have the intrinsic ability to bind to the ocular surface and can be loaded with different drugs. Here, we report DNA NPs functionalized for loading of brimonidine through specific aptamers and via hydrophobic interactions with double stranded micelles. Both NP systems exhibited improved affinity toward the cornea and retained release of the drug as compared to controls both in vitro and in vivo. Both NP types were able to lower the IOP in living animals significantly more than pristine brimonidine. Importantly, the brimonidine-loaded NPs showed no toxicity and improved efficacy and hence should improve compliance. In conclusion, this drug-delivery system offers high chances of an improved treatment for glaucoma and thus preserving vision in the aging population.
AB - Glaucoma is the second leading cause of irreversible blindness worldwide. Among others, elevated intraocular pressure (IOP) is one of the hallmarks of the disease. Antiglaucoma drugs such as brimonidine can lower the IOP but their adherence to the ocular surface is low, leading to a low drug uptake. This results in a frequent dropping regime causing low compliance by the patients. Lipid DNA nanoparticles (NPs) have the intrinsic ability to bind to the ocular surface and can be loaded with different drugs. Here, we report DNA NPs functionalized for loading of brimonidine through specific aptamers and via hydrophobic interactions with double stranded micelles. Both NP systems exhibited improved affinity toward the cornea and retained release of the drug as compared to controls both in vitro and in vivo. Both NP types were able to lower the IOP in living animals significantly more than pristine brimonidine. Importantly, the brimonidine-loaded NPs showed no toxicity and improved efficacy and hence should improve compliance. In conclusion, this drug-delivery system offers high chances of an improved treatment for glaucoma and thus preserving vision in the aging population.
U2 - 10.1021/acsami.0c18626
DO - 10.1021/acsami.0c18626
M3 - SCORING: Journal article
C2 - 33528240
VL - 13
SP - 9445
EP - 9456
JO - ACS APPL MATER INTER
JF - ACS APPL MATER INTER
SN - 1944-8244
IS - 8
ER -
